China leads in absolute trial volume for cirrhosis stem-cell therapy, but regulatory oversight and publication standards vary. Germany, Spain, Italy, and France conduct well-documented European trials with university hospital affiliation and international publication. South Korea maintains active liver-fibrosis-specific MSC research. United States cirrhosis trials are less numerous but often embedded in transplant centres with rigorous safety monitoring. Poland and Czech Republic offer lower-cost access to active protocols. Selection should prioritise centres affiliated with established hepatology institutions, ClinicalTrials.gov registration, and published safety outcomes over marketing.
Cirrhosis stem-cell treatment costs typically range €3,500–8,000 per cycle, reflecting the complexity of cell expansion, multiple infusions, and intensive hepatological monitoring required. Systemic intravenous infusion and hepatic artery catheterisation (in selected protocols) add procedural costs. Cell dose is often higher for cirrhosis than joint-specific conditions, increasing manufacturing expense. Hospital-based programmes with on-site cell facilities typically charge less than standalone private clinics. Ancillary costs — imaging, lab testing, gastroenterology evaluation, variceal screening — substantially increase total per-cycle expense. European university hospitals generally offer lower rates than private boutique providers.
Am I a candidate? → · Liver Cirrhosis: full overview → · Liver Cirrhosis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача